Navigation Links
Assisted Breathing Eases Lung Symptoms for Heart Patients
Date:7/9/2008

rapy (9.8 percent of patients) and those with assisted breathing (9.5 percent).

The percentage of those getting assisted breathing who died or required more serious intervention in those seven days was about the same for CPAP (11.7 percent) and NIVVP (11.1 percent).

The improvement in symptoms means that assisted breathing is worth using for pulmonary edema, Baas said. "It did make people feel more comfortable," he noted.

Both methods are readily available in hospitals, Baas said, but CPAP probably is preferable because it is in wider use by people with sleep apnea, who can do it at home, he explained.

More information

Pulmonary edema and its treatment are described by the U.S. Library of Medicine.



SOURCES: Arnold Baas, M.D., assistant professor, medicine, University of California, Los Angeles; July 10, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New Coalition Presses for Quality Standards for Assisted Living Facilities in PA
2. As I-1000 Signatures are Counted, Washington State Medical Association Opposition to Physician-Assisted Suicide Reiterated
3. AdCare Health Systems, Inc. Announces the Refinancing of Three Assisted Living Properties in Ohio
4. A Place for Mom, Nations Largest Assisted Living and Senior Housing Referral Service Announces New Vice President of Finance
5. Californians Against Assisted Suicide - Controversial Bill, AB 2747 Narrowly Passes Assembly
6. Assisted Living Industry Looks at Future of Alzheimers
7. American Humane Forms Human-Animal Bond Division, Including Animal-Assisted Therapy, Humane Ed and Pets & Womens Shelters
8. New National Survey: 84% of Americans Over 50 Expect a Family Member to Move into an Assisted Living Community Within the Next 10 Years
9. Robot-assisted minimally-invasive CABG surgery
10. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
11. Ethicon Endo-Surgery Submits Application to FDA for Approval of the SEDASYS(TM) System - the First Computer-Assisted Personalized Sedation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Regents Health Resources, a consulting firm traditionally specializing ... industry veteran Daryl Demonbreun and former St. Thomas executive ... ambitious plans to grow into a full-service health care ... at a steady pace for nearly 20 years, but ... Bob Maier, founder and chief executive officer of Regents ...
(Date:7/29/2014)... Saint Luke’s Medical Group’s 11 ... Patient-Centered Medical Home 2011 Level 3 Recognition—the highest ... Assurance. Only one out of four physicians' groups ... or Level 3 recognition. , Patients of primary ... report faster access to their doctors, better outcomes ...
(Date:7/29/2014)... The Mesothelioma Applied Research Foundation (Meso ... led advocacy efforts among its members for increased ... Caucus on the Deadliest Cancers. , As a ... following 20 members: , Rep. Matt Salmon (AZ-5) – June ... Rep. Zoe Lofgren (CA-19) – June 19, 2014, Rep. Adam ...
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 The One ... created by Alison Freeman, an herbal medicine specialist. Alison Freeman ... their herpes condition. , People interested in finding out ... Internet and can download it, as it is currently available ... a variety of natural remedies and herbal medicine tips that ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... created by a holistic nutritional and functional medicine practitioner, who ... overcoming this problem. , Karen suffered from leaky gut, too, ... time to develop this unique treatment. , Karen Brimeyer ... with sufferers from all around the world. The author of ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2
... the real thing may go further than first thought.Violent ... that makes people more likely to behave aggressively, says ... considered the effects of popular games such as Doom, ... killings, high-powered weaponry and street crime, indicates that avid ...
... Milwaukee Cardiologist, and Chief of the Specialty Hospital in ... dire need of a shot in the arm.//Specialty Hospitals ... prevailing healthcare systems, was nipped in the bud, owing ... opinion write-up in The Wall Street Journal, has expressed ...
... in every 100,000 in India suffer from stroke every year. ... Tamil Nadu for promoting awareness with regard to stroke in ... is very low.// ,The Indian Stroke Association ... a study report here which says around 20 million people ...
... between office work and private life, as they feel that ... during evenings and weekends //when they are with their family ... hours they find the mobile phones and pagers ringing from ... and work concentration. Most of the people feel that work ...
... and Industrial Research Organization (CSIRO) may increase the ... Nutritionist. //Dr. Stanton has asked the Australian Prime ... in recommending CSIRO diet as it contains high ... recommend the Australian Governments Australian Guide to Healthy ...
... Orr, a Canadian woman who has survived breast cancer twice, ... Herceptin. //Orr says that the life-saving and life-improving drug should ... deadly cancer have a chance of successfully fighting it. ... drug is federally funded in some provinces, while it is ...
Cached Medicine News:Health News:Violent computer games spur aggression: study 2
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... 29  2014 ISPE—the International Society for Pharmaceutical ... Bournas as President and CEO, succeeding ... the Society last fall.  Mr. Bournas takes the ... healthcare association industry as well as significant international ... vision for the expansion of its global initiatives ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: